NEXI
Closed
Neximmune Inc
0.0001
0.0000 (0.00%)
Last Update: 01 Jul 2025 16:30:00
Yesterday: 0.0001
Day's Range: 0.0001 - 0.0001
Send
sign up or login to leave a comment!
When Written:
0.4
Neximmune Inc is a clinical-stage biotechnology company that develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company's proprietary platform technology, called Artificial Immune Modulation (AIM), enables the identification and engineering of immune cells with enhanced therapeutic properties.
Neximmune's lead product candidate, NEXI-001, is an AIM-enabled T cell therapy for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The company is also developing AIM-enabled therapies for solid tumors and autoimmune diseases.
Neximmune was founded in 2015 and is headquartered in Gaithersburg, Maryland. The company has raised over $70 million in funding from investors, including NEA, Pfizer Ventures, and H.I.G. BioHealth Partners.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Neximmune's lead product candidate, NEXI-001, is an AIM-enabled T cell therapy for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The company is also developing AIM-enabled therapies for solid tumors and autoimmune diseases.
Neximmune was founded in 2015 and is headquartered in Gaithersburg, Maryland. The company has raised over $70 million in funding from investors, including NEA, Pfizer Ventures, and H.I.G. BioHealth Partners.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








